774605-35-5

Upstream product

• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 7152-15-0 ethyl 4-methyl-3-oxo-pentanoate 
• 6579-27-7 2,6-Dichloro-N-hydroxybenzenecarboximidoyl chloride 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 6575-28-6 (1E)-2,6-dichlorobenzaldehyde oxime 
• 3714-77-0 2,6-dichlorobenzaldoxime 
• 25185-95-9 2,6-dichlorobenzaldoxime 

Downstream Products

• 278597-30-1 [3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methanol 
• 700835-81-0 4-(chloromethyl)-3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole 
• 1268245-11-9 3-(2-(2-chloro-4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)phenyl)cyclopropyl)benzoic acid 
• 1020570-56-2 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carbaldehyde 
• 1268246-39-4 C₁₄H₁₅Cl₂NO₃ 
• 1268246-38-3 C₂₀H₂₉Cl₂NO₃Si 

Relevant academic research and scientific papers

HETEROCYCLIC FXR MODULATORS

The present technology is directed to compounds of formula (I), compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease.

Novel FXR (NR1H4) binding and activity modulating compounds

The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.

NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS

The present invention relates to compounds which bind to the NR1 H4 receptor (FXR) and act as agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.

Novel isoxazole carboxamides as growth hormone secretagogue receptor (GHS-R) antagonists

Novel isoxazole carboxamides have been identified as growth hormone secretagogue receptor (GHS-R) antagonists. Substituent modification off the 5-position of the isoxazole ring led to analogues with potent binding affinity and functional antagonism of GHS-R. A potent analogue (32) with high aqueous solubility and good GPCR selectivity was also identified as a potential pharmacological tool for in vivo studies.